Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Total Liabilities (2016 - 2025)

Historic Total Liabilities for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $1.9 million.

  • NovaBay Pharmaceuticals' Total Liabilities fell 3393.94% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 3393.94%. This contributed to the annual value of $3.6 million for FY2024, which is 3790.21% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Total Liabilities of $1.9 million as of Q3 2025, which was down 3393.94% from $2.7 million recorded in Q2 2025.
  • NovaBay Pharmaceuticals' 5-year Total Liabilities high stood at $13.8 million for Q4 2021, and its period low was $1.9 million during Q3 2025.
  • Moreover, its 5-year median value for Total Liabilities was $5.2 million (2024), whereas its average is $5.2 million.
  • Over the last 5 years, NovaBay Pharmaceuticals' Total Liabilities had its largest YoY gain of 37284.25% in 2021, and its largest YoY loss of 8051.92% in 2021.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Total Liabilities stood at $13.8 million in 2021, then tumbled by 57.67% to $5.8 million in 2022, then decreased by 2.14% to $5.7 million in 2023, then plummeted by 37.9% to $3.6 million in 2024, then tumbled by 47.83% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $2.7 million for Q2 2025, and $3.7 million during Q1 2025.